Prevention & lipidsCohort study
Sustainable and effective lipid-lowering management: prevention strategies from the BRING-UP prevention study
- nationwide, observational, prospective, multicenter study
- two 3-month enrolment phases followed by a 6-month follow-up
- each phase preceded by an educational intervention
Authors' conclusion
BRING-UP prevention achieved its primary goal to increase the percentage of patients at the LDL-C goal, demonstrating that, in many patients, this goal can be achieved by increasing the use of low-cost therapies.
Study context
- Population
- Patients with a prior atherothrombotic event, enrolled by cardiology centresrecruited by 189 cardiology centres over 3 months (first enrolment phase), follow-up data at 6 months for 4643 patients (97%), LDL-C available for 4334 of them
- Participants
- 4,790 patients
- Exposure
- the percentage of patients at goal for LDL-cholesterol (LDL-C) (<55 mg/dL) at the 6-month follow-up in the recently completed first enrolment phase
Main finding
As reported in the abstract
Percentage of patients at goal for LDL-C (<55 mg/dL) · 6-month follow-up
Rate of patients with LDL-C < 55 mg/dL, from
33%
Rate of patients with LDL-C < 55 mg/dL, to
58.1%
Absolute increase
25.1%
Relative increase
76.1%
Observational data: associations, not effects.
Secondary outcomes
Lipid-lowering prescriptions · 6 months
- Patients prescribed statins
- 94.9%
- Ezetimibe prescribed
- 84%
- PCSK9i monoclonal antibodies and inclisiran prescribed
- 8.3%
- Atorvastatin and rosuvastatin the most prescribed statins, mostly at high doses
Follow-up completeness · 6 months
- Follow-up data available
- 4643 patients (97%)
Original publication
Sustainable and effective lipid-lowering management: prevention strategies from the BRING-UP prevention study. Eur Heart J Qual Care Clin Outcomes. Published 8 February 2026. doi:10.1093/ehjqcco/qcag021
Summarised from the published abstract; every number is checked against it